Kailera Therapeutics (NAS: KLRA) key facts
- Kailera Therapeutics Inc is a clinical-stage biotechnology company.
- Kailera Therapeutics (NAS: KLRA)’s last known valuation is $1.5B (Oct 2025).
- It has raised $1.6B; the latest was IPO ($625.0M) in Apr 2026.
- Notable investors include Qatar Investment Authority, Bain Capital, The Invus Group, RTW Investments, Atlas Venture — 14 tracked in total.
- 2 institutional filers report fund marks on Kailera Therapeutics (NAS: KLRA) across 8 filings.
- Status: Publicly Held.
Who backs Kailera Therapeutics (NAS: KLRA)
14+- ·The complete investor list: 14 names
- ·Watch Kailera Therapeutics (NAS: KLRA): the Monday email on marks, rounds and moves
Kailera Therapeutics (NAS: KLRA) funding rounds
No funding rounds for Kailera Therapeutics (NAS: KLRA) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kailera Therapeutics (NAS: KLRA) valuation
Kailera Therapeutics (NAS: KLRA) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.5 billion (Oct 2025). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.
Recent activity
In the last 90 days, Kailera Therapeutics (NAS: KLRA)'s record added 3 institutional fund marks (latest period Jul 2026).
Institutional holders and vehicles
2 SEC-registered funds reported 8 fair-value marks on Kailera Therapeutics (NAS: KLRA) between Apr 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Kailera Therapeutics (NAS: KLRA) investors
14 investors are on record for Kailera Therapeutics (NAS: KLRA), including Qatar Investment Authority, Bain Capital, The Invus Group and RTW Investments. By type, the record holds 4 hedge funds, 2 private equity firms and 1 venture capital firm.
About Kailera Therapeutics (NAS: KLRA)
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2024
- Employees
- 140
- Website
- kailera.com/
- Ownership
- Publicly Held
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kailera Therapeutics (NAS: KLRA)’s last known valuation, Oct 2025. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.
Institutional fund marks on Kailera Therapeutics (NAS: KLRA)
2 filers · latest Jul 20262 SEC-registered funds reported 8 fair-value marks on Kailera Therapeutics (NAS: KLRA) between Apr 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View